Zobrazeno 1 - 10
of 48
pro vyhledávání: ''
Autor:
Andrea De Giglio, Valeria Grandinetti, Marta Aprile, Greta Borelli, Anita Campus, Anna Laura Croci Chiocchini, Marco Busutti, Gisella Vischini, Alessandro Di Federico, Francesca Sperandi, Barbara Melotti, Andrea Ardizzoni, Gaetano La Manna, Francesco Gelsomino
Publikováno v:
Lung Cancer. 174:91-96
The combination of immune-checkpoint inhibitors (ICI) and platinum-pemetrexed chemotherapy (CT) in first-line setting improved survival outcomes of advanced non-small cell lung cancer (NSCLC) patients. Among the various adverse events, renal toxicity
Autor:
Didier, Debieuvre, Charles, Dayen, Adrien, Dixmier, David, Pau, Anna, Sibley-Revelat, William, Greenwood, Samuel, Gally, Lionel, Falchero
Publikováno v:
Lung Cancer. 164:1-7
FRESC reanalyzed extensive-stage small-cell lung cancer (ES-SCLC) patient data from the French KBP-2010 cohort to describe the characteristics and therapeutic management of ES-SCLC and provide real-world estimates of survival.A target population of f
Publikováno v:
Lung Cancer
Objectives Second-line immune checkpoint inhibition (ICI) was recently shown to have a survival advantage over placebo in malignant pleural mesothelioma (MPM), but the survival comparison to chemotherapy in patients with MPM receiving routine clinica
Autor:
Isamu Okamoto, Yuichi Takiguchi, Nobuyuki Yamamoto, Ichiro Yoshino, Takehito Shukuya, Etsuo Miyaoka, Koichi Takayama, Kazuhisa Takahashi, Yasushi Shintani, Meinoshin Okumura, Katsuhiko Naoki, Satoshi Igawa, Ikuo Sekine, Katsuyuki Kiura, Akira Inoue
Publikováno v:
Lung Cancer. 146:160-164
Objectives Most patients with small-cell lung cancer (SCLC) experience relapse because of the emergence of drug-resistant tumor cells. Therefore, second-line therapy is subsequently required to prolong their survival. However, it is unclear whether s
Autor:
Anas Gazzah, Pilar Garrido, Alexis B. Cortot, Jaafar Bennouna, Melissa Lynne Johnson, Maciej Gil, Haruyasu Murakami, Benjamin Besse
Publikováno v:
Lung Cancer. 142:63-69
Objectives Efficacy and safety of necitumumab when combined with pembrolizumab was assessed in patients with Stage IV non-small cell lung cancer (NSCLC) of squamous and nonsquamous histology, who had progressed after treatment with a platinum-based d
Autor:
Alvin Soon Tiong Lim, Quan Sing Ng, Anantham Devanand, Daniel S.W. Tan, T. Rajasekaran, Eng Huat Tan, Zaw Win Aung, Chee Keong Toh, G. Lai, Chow Wei Too, Tony Kiat-Hon Lim, Aaron C. Tan, Bien Soo Tan, Tina P.T. Koh, Tse Hui Lim, Mei-Kim Ang, Angela Takano, Wan Ling Tan, Shou Yu Poon, Brett Doble, Apoorva Gogna, Amit Jain, Boon-Hean Ong, Ravindran Kanesvaran, Wan-Teck Lim, Gek San Tan
Publikováno v:
Lung Cancer. 139:207-215
Objectives There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling traditional single biomarker assays from small biopsie
Publikováno v:
Lung Cancer. 138:52-57
Brain metastasis (BM) is common in patients with epidermal growth factor receptor (EGFR)-mutant lung cancer. However, the brain surveillance strategy during treatment in advanced lung cancer patients varies, and the impact on clinical outcome is uncl
Autor:
Santiago Viteri, Santiago Ramón y Cajal, José Ignacio Toscas, Irene Moya-Horno, José Antonio Maestre-Alcácer, Rafael Rosell, Laura Romero-Vielva
Publikováno v:
Lung Cancer. 133:117-122
Introduction Despite all treatment advances, lung cancer is still the main cause of death worldwide. Treatment for resectable stage IIIA remains controversial including definitive chemoradiotherapy and induction treatment followed by surgery. After d
Autor:
Takashi Seto, Kazuki Takada, Mototsugu Shimokawa, Yoshihiko Maehara, Akira Haro, Atsushi Osoegawa, Yoshinao Oda, Tetsuzo Tagawa, Kenichi Kohashi
Publikováno v:
Lung Cancer. 128:26-32
Objectives Combination therapy with an inhibitor of indoleamine 2, 3-dioxygenase 1 (IDO1) and an agent targeting programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) is expected to be a novel and effective treatment option for variou
Autor:
Akihiko Ito, Kaoru Tanaka, Kazuhiko Nakagawa, Yasushi Nakamura, Masayuki Takeda, Hitomi Sakai, Kazuto Nishio, Hidetoshi Hayashi, Kazuko Sakai
Publikováno v:
Lung Cancer. 127:59-65
Objectives Immune-checkpoint inhibitors (ICIs) are now an established therapeutic option for advanced non–small cell lung cancer (NSCLC). It has remained unclear, however, whether cytotoxic chemotherapy affects the immune microenvironment in NSCLC